{
    "clinical_study": {
        "@rank": "38559", 
        "arm_group": [
            {
                "arm_group_label": "DTP/HB/Hib vaccine", 
                "arm_group_type": "Experimental", 
                "description": "Group A will receive DTP/HB/Hib combination vaccine at 6-11, 10-15 and 14-19 weeks of age.\nDTP/HB/Hib component:\nPurified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal"
            }, 
            {
                "arm_group_label": "DTP/HB and Hib vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "Group B will receive DTP/HB and Hib Vaccines separately at 6-11,10-15, 14-19 weeks of age\nDTP/HB component:\nPurified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis rHbsAg Aluminum phosphate Natrium Chloride Thimerosal\nHib component:\nPurified Haemophilus influenzae type b polysaccharide 10 mcg"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of this study was to evaluate the protectivity and safety  of DTP/HB/Hib\n      (Bio Farma) vaccine compared to DTP/HB and Hib vaccine given simultaneously."
        }, 
        "brief_title": "Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine", 
        "completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This trial was randomized, single blind, prospective intervention study. Total 220 subject\n      (6-11 weeks of ages) followed this trial, divided into 2 groups, each group consists of 110\n      subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Infant 6-11 week of age\n\n          -  Infant born after 37-42 week of pregnancy\n\n          -  Infant weighing more than 2.5 kg at birth\n\n          -  Father, mother or legally acceptable representative properly informed about the study\n             and having signed the informed consent form\n\n          -  Parents commit themselves to comply with the indication of the investigator and with\n             the schedule of the trial\n\n          -  Mother at least graduate from elementary school\n\n          -  Received Hepatitis B vaccine (Bio Farma) at birth\n\n        Exclusion Criteria:\n\n          -  Child concomitantly enroll or schedule to be enroll in another trial\n\n          -  Evolving moderate or severe illness, especially infectious diseases or fever\n             (axillary temperature >=37.5 Celsius on Day 0)\n\n          -  Known history of allergy to any component of the vaccine component (e.g.formaldehyde)\n\n          -  History of uncontrolled coagulopathy or blood disorder contraindicating intramuscular\n             injection\n\n          -  Known history of congenital or acquired immunodeficiency (including HIV infection)\n\n          -  Child who has received in the previous 4 weeks a treatment likely to alter the immune\n             response (intravenous immunoglobulin, blood derived product or long term\n             corticotherapy (>2 weeks)\n\n          -  Other vaccination within the 7 days prior to inclusion with the exception of BCG and\n             poliomyelitis\n\n          -  Any abnormality or chronic disease which according to the investigator might\n             interfere with the assessment of the trial objective\n\n          -  Infant with a known history of diphteria, tetanus, pertussis, Hib, Hepatitis B\n             infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "11 Weeks", 
            "minimum_age": "6 Weeks"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986322", 
            "org_study_id": "Penta 0211"
        }, 
        "intervention": [
            {
                "arm_group_label": "DTP/HB/Hib vaccine", 
                "description": "Dosage equal to 0.5 mL administered intramuscularly", 
                "intervention_name": "DTP/HB/Hib  vaccine", 
                "intervention_type": "Biological", 
                "other_name": "Pentavalent"
            }, 
            {
                "arm_group_label": "DTP/HB and Hib vaccine", 
                "description": "Dosage equal to 0.5 mL administered intramuscularly", 
                "intervention_name": "DTP/HB and Hib vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "DTP/HB/Hib vaccine", 
            "Immunogenicity", 
            "Infants", 
            "Safety"
        ], 
        "lastchanged_date": "November 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Garuda Primary Health Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Puter Primary Health Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java"
                    }, 
                    "name": "Ibrahim Adji Primary Health Care Center"
                }
            }
        ], 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2 Study of Immunogenicity and Safety of DPT/HB/Hib (Bio Farma) Vaccine Compared to DTP/HB (Bio Farma) Vaccine Given Simultaneously With Hib (Registered) Vaccine in Indonesian Infants", 
        "overall_official": {
            "affiliation": "Faculty of Medicine UNPAD", 
            "last_name": "Kusnandi Rusmil, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Percentage of infants with anti diphteria titer and anti tetanus titer >= 0.01 IU/ml, AntiHbs titer >=10mlIU/ml, and antiPRP-TT titer >= 0,15ug/ml 28 days after the last injection (third) in DPT/HB/Hib liquid vaccine group", 
            "measure": "Protectivity of DTP/HB/Hib (Bio Farma) vaccine", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986322"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Serological response to diphteria toxoid:  GMT, percentage of infants with titer >=0.01 IU/ml and >=0.1 IU/ml, percentage of infants with increasing antibody titer >=4 times and/or percentage of infants with transition of seronegative to seropositive.", 
                "measure": "Antibody response to diphteria toxoid in both group", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Serological response to tetanus toxoid: GMT, percentage of infants with titer >=0.01 IU/ml and >=0.1 IU/ml, percentage of infants with increasing antibody titer >=4 times and/or percentage of infants with transition of seronegative to seropositive", 
                "measure": "Antibody response to Tetanus Toxoid in both group", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Serological response to the pertussis component (agglutinins): GMT,percentage of infants with titre >=40, >=80,>=160 and >=320 (1/dil.), percentage of infants with increasing antibody titer >=4 times.", 
                "measure": "Antibody response to Pertussis component in both group", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Serological response to Hepatitis B:  Geometric mean of anti-HBs, percentage of infants with titer >=10mlIU/ml, percentage of infants with increasing antibody titer >=4 times and/ or percentage of infants with transition of seronegative to seropositive.", 
                "measure": "Antibody response to Hepatitis B in both group", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Serological response to Hib/PRP: GMT, percentage of infants with titre >=1ug/ml and >=0.15ug/ml, percentage of infants with increasing antibody     titer >=4 times and/or percentage of infants with transition of seronegative to seropositive", 
                "measure": "Antibody response to PRP-T in both group", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Local and systemic reaction", 
                "measure": "Incidence rate of adverse event of DTP/Hepatitis B/Hib vaccine (Bio Farma)", 
                "safety_issue": "Yes", 
                "time_frame": "30 minutes, 72 hours, 28 days after immunization"
            }
        ], 
        "source": "PT Bio Farma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PT Bio Farma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}